SOM Biotech announces its participation at the BIO-Partnering at JP Morgan Healthcare Conference 2021, being held virtually on January 11th – 15th.

The conference, a leading virtual partnering and business development initiative for the biotechnology industry organized by Biotechnology Innovation Organization, provides a One-on-One partnering platform to give companies access to potential strategic partners and qualified investors worldwide.

Raúl Insa, CEO of SOM Biotech highlights: “This is an excellent opportunity to present the advances in our portfolio and explore mutual interest with pharmaceutical and other life science companies to seek new drug discovery and development projects based on our proprietary AI-based drug discovery technology – SOMAIPRO – which is one of the most powerful tools for drug discovery at present. After closing the remarkable year 2020, with positive results obtained from the Phase 2a related to our Huntington´s disease candidate SOM3355, we are also excited to present our pipeline assets and our strategic plan to investors interested in taking part in our future valuable launches and growth prospects”.

Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream